摘要
目的:探讨原发性高血压患者中血管紧张素Ⅱ2型受体基因A1675G单核苷酸多态性与高血压发生及缬沙坦治疗的关系。方法:应用直接测序方法对80例原发性高血压和40例正常人群中血管紧张素Ⅱ2型受体基因作SNP分型。结果:原发性高血压患者A1675G位点上A等位基因频率和正常人群中相比有统计学意义(P<0.05);其与用药后血压的下降幅度有统计学意义(P<0.05)。结论:血管紧张素Ⅱ2型受体基因的A1675G单核苷酸多态性与原发性高血压发病有关,其可能是缬沙坦降压疗效的新的预测因子。
AIM： To study the relation of single nucleotide polymorphism of angiotensin II receptor 2（AGTR2） A1675G with essential hypertension （EH） and antihypertensive response to valsartan. METHODS： Eighty case essential hypertension patients were received valsartan once daily for four weeks. Direct DNA sequencing was performed to detect the signgle nucleotide polymorphisms in eighty patients with essential hypertension and fourty normal blood pressure controls. RESULTS：There were significant differences of A1675G allele frequency between hypertensive group and normal controls（P〈 0.05）. Treated with valsartan, patients with A allele had greater reduction in blood pressure （P 〈 0.05）. CONCLUSION.. The results indi- cates that the AGTR2 A1675G single nucleotide polymorphisms might involved the development of essential hypertension and it is associated with antihypertensive predictor of valartan.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2012年第2期185-188,共4页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
南京军区医学科技创新课题(08MB129)
关键词
高血压
血管紧张素Ⅱ
受体
单核苷酸多态性
缬沙坦
Hypertension
Angiotensin II
Receptor
Single nucleotide polymorphisms
Valartan
